y's election to draw down funds
pursuant to the committed equity financing facility entered into with
Kingsbridge Capital Limited in May 2008, as well as the common stock
issuable upon exercise of an outstanding warrant issued to Kingsbridge in
connection with the transaction. If and when declared effective by the SEC,
the resale registration statements will allow the selling securityholders
named therein to publicly resell shares of the company's common stock
issuable pursuant to the committed equity financing facility and upon the
exercise of the above-referenced warrants, as applicable. Written
prospectuses, when available, may be obtained from Jazz Pharmaceuticals at
3180 Porter Drive, Palo Alto, California 94304, Attention: Investor
Relations.
The registration statements relating to these securities have been
filed with the SEC but have not yet become effective. These securities may
not be sold, nor may offers to buy be accepted prior to the time the
applicable registration statement becomes effective. This press release
shall not constitute an offer to sell, or the solicitation of an offer to
buy, nor shall there be any sale of the securities in any state in which
such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is a specialty pharmaceutical company focused on
identifying, developing and commercializing innovative products to meet
unmet medical needs in neurology and psychiatry. For further information
see http://www.JazzPharmaceuticals.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform
Act of 1995
This press release contains forward-looking statements, including, but
not limited to, statements related to the offering of securities by Jazz
Pharmaceuticals and the issuance of additional debt under an ex
'/>"/>
SOURCE Jazz Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference2.
Merrimack Pharmaceuticals Raises $60 Million in Private Financing3.
The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia4.
Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors5.
Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals6.
Amira Pharmaceuticals Hires Industry Veteran for CFO Position7.
Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter8.
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease9.
Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference10.
Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference11.
LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests